FDA.reportPublic FDA data

abacavir 600 MG / dolutegravir 50 MG / 3TC 300 MG Oral Tablet [Triumeq]

RxCUI
1546894
RxNorm name
abacavir 600 MG / dolutegravir 50 MG / 3TC 300 MG Oral Tablet [Triumeq]
Display name
abacavir 600 MG / dolutegravir 50 MG / 3TC 300 MG Oral Tablet [Triumeq]
Full name
abacavir 600 MG / dolutegravir 50 MG / 3TC 300 MG Oral Tablet [Triumeq]
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:51

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TriumeqABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINEViiV Healthcare Company2997739a-aa91-42aa-a206-a70e2db7b84f2024-07-08Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 1546894

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
2997739a-aa91-42aa-a206-a70e2db7b84fTriumeq 600 MG / 50 MG / 300 MG Oral Tablet [PSN] · abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [Triumeq] [SBD] · abacavir 600 MG / dolutegravir 50 MG / 3TC 300 MG Oral Tablet [Triumeq] [SY] · Triumeq (abacavir 600 MG / dolutegravir 50 MG / lamivudine 300 MG) Oral Tablet [SY]430These highlights do not include all the information needed to use TRIUMEQ and TRIUMEQ PD safely and effectively. See full prescribing information for TRIUMEQ and TRIUMEQ PD. TRIUMEQ (abacavir, dolutegravir, and lamivudine) tablets, for oral use TRIUMEQ PD (abacavir, dolutegravir, and lamivudine) tablets for oral suspension Initial U.S. Approval: 201420240708